Spotlight and Briefings
Back to feedNavigate 7-day Briefings
WHO approves first Bundibugyo diagnostic test and begins clinical trial for treatments as outbreak surpasses 1,400 cases in DRC.
7 day briefing • 2026-07-03 - 2026-07-09 (2 weeks ago) • rolling
This week marked significant progress in the response to the Bundibugyo virus (BDBV) outbreak in the Democratic Republic of the Congo (DRC) and Uganda. On 2 July 2026, the World Health Organization (WHO) added the first molecular diagnostic test for BDBV to its Emergency Use Listing (EUL), enabling rapid detection of viral genetic material in blood samples. This development follows the 17 May 2026 declaration of a Public Health Emergency of International Concern (PHEIC) for the outbreak.
Concurrently, WHO-sponsored PARTNERS platform trial began enrolling patients in the DRC to evaluate MBP134 (a monoclonal antibody) and remdesivir as treatments for Bundibugyo virus disease (BVD), for which no approved therapies exist. The outbreak has been severe, with DRC alone reporting 1,406 confirmed cases and 438 deaths as of the announcements. Laboratory capacity in the DRC has expanded from 200–400 tests per day at two sites to over 2,000 tests per day across ten laboratories.
Additional EUL applications and a joint validation platform with Africa CDC, PATH, FIND, CHAI, and Unitaid are underway, while the PARTNERS trial integrates with outbreak response support from ALIMA and MSF. These coordinated efforts represent critical steps in controlling the outbreak and developing effective countermeasures.
Navigate Timescales
2026-07-03 - 2026-07-09
2026-06-10 - 2026-07-09
2026-04-11 - 2026-07-09
2025-07-10 - 2026-07-09
Each tier targets the nearest available window end date to this briefing.
Pillar Signal Heatmap
| Pillar | 7d | Trend |
|---|---|---|
|
Outbreak Tracking
|
|
|
|
Transmission Dynamics
|
|
|
|
Medical Countermeasures
|
|
|
|
Humanitarian Response
|
|
|
|
Health Systems Resilience
|
|
|
|
Policy & Governance
|
|
Intensity is derived from pillar keyword overlap with headline, summary, key signals, and themes for each horizon.
Trend uses last 5 entries in this 7-day timescale (rightmost point is current).
Key Signals
- - WHO added first BDBV molecular diagnostic test to Emergency Use Listing on 2 July.
- - PARTNERS trial began enrollment for MBP134 monoclonal antibody and remdesivir treatments.
- - DRC outbreak reported 1,406 confirmed cases and 438 deaths as of 2 July.
- - Lab capacity in DRC increased from 200-400 tests/day at 2 sites to over 2,000 tests/day at 10 labs.
- - Additional EUL applications and joint validation platform with Africa CDC, PATH, FIND, CHAI, and Unitaid are underway.
- - PARTNERS trial is supported by ALIMA and MSF and includes independent data safety monitoring board.
Top Themes
Key References
-
WHO adds first molecular diagnostic test for Ebola Bundibugyo virus to Emergency Use Listing
[rss]
First molecular diagnostic test added to EUL, a key step in outbreak response.
-
PARTNERS clinical trial begins enrolment for Bundibugyo virus disease treatments in the Democratic Republic of the Congo
[rss]
Enrollment begins for first clinical trial evaluating treatments for BVD.